The 30 references in paper S. Avdeev N., Z. Aisanov R., С. Авдеев Н., З. Айсанов Р. (2016) “МАКСИМАЛЬНАЯ БРОНХОДИЛАТАЦИЯ СО СТАРТА ТЕРАПИИ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ: ВЛИЯНИЕ НА ТЕЧЕНИЕ ЗАБОЛЕВАНИЯ // MAXIMAL BRONCHODILATION WITH STARTING THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN INFLUENCE ON THE COURSE OF THE DISEASE” / spz:neicon:pulmonology:y:2016:i:5:p:604-609

1
Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2017. GOLD website (www.goldcopd.com).
(check this in PDF content)
2
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и соавт. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54.
(check this in PDF content)
3
Anthonisen N.R., Wright E.C., the IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis.1986; 133: 814–819.
(check this in PDF content)
4
Hanania N.A., Sharafkhaneh A., Celli B. et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir. Res. 2011, 12: 6.
(check this in PDF content)
5
Авдеев С.Н. Роль легочной гиперинфляции в патогенезе ХОБЛ. Эффективность поддерживающей терапии в уменьшении легочной гиперинфляции. Пульмонология. 2004; 6: 101–110.
(check this in PDF content)
6
Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med.2015; 109: 785–802.
(check this in PDF content)
7
O’Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.1998; 158: 1557–1565.
(check this in PDF content)
8
Casarosa P., Bouyssou T., Germeyer S.et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Pharmacol. Exp. Ther. 2009; 330: 660–668.
(check this in PDF content)
9
Rennard S., Bantje T., Centanni S. et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir. Med. 2008; 102: 1033–1044.
(check this in PDF content)
10
Singh D., Magnussen H., Kirsten A. et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm. Pharmacol. Ther.2012; 25: 248–253.
(check this in PDF content)
11
Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.
(check this in PDF content)
12
Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003; 58: 659–664.
(check this in PDF content)
13
Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des. Devel. Ther.2013; 7: 1201–1208.
(check this in PDF content)
14
Beeh K.-M., Westerman J., Kirsten A.-M. et al. The 24-h lung function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther.2015; 32: 53–59.
(check this in PDF content)
15
Buhl R. Maltais F. Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45: 969–979.
(check this in PDF content)
16
Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium+olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther.2015; 32: 523–536.
(check this in PDF content)
17
Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med.2015; 109: 1312–1319.
(check this in PDF content)
18
Profita M., Bonanno A., Montalbano A.M. et al. Beta2-longacting and anticholinergic drugs control TGF β1-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 2012; 1822: 1079–1089.
(check this in PDF content)
19
Price D., Freeman D., Cleland J. et al. Earlier diagnosis and earlier treatment of COPD in primary care. Prim. Care Respir. J.2011; 20: 15–22.
(check this in PDF content)
20
Lee J.Y., Rhee C.K., Jung K.S., Yoo K.H. Strategies for management of the early chronic obstructive lung disease. Tuberc. Respir. Dis.2016; 79: 121–126.
(check this in PDF content)
21
Авдеев С.Н. Выбор оптимальной терапии при ранних стадиях хронической обструктивной болезни легких. Справочник поликлинического врача.2009; 11: 27–31.
(check this in PDF content)
22
Rennard S., Decramer M., Calverley P.M. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur. Respir. J.2002; 20: 799–805.
(check this in PDF content)
23
Pinto-Plata V.M., Celli-Cruz R.A., Vassaux C. et al. Differences in cardiopulmonary exercise test results by American Thoracic Society / European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest. 2007; 132; 1204–1211.
(check this in PDF content)
24
Watz H., Waschki B., Meyer T., Magnussen H. Physical activity in patients with COPD.Eur. Respir. J.2009; 33: 262–272.
(check this in PDF content)
25
Hole D.J., Watt G.C., Davey-Smith G. et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–715.
(check this in PDF content)
26
Schunemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000; 118: 656–664.
(check this in PDF content)
27
Tantucci C., Modina D. Lung function decline in COPD. Int. J. COPD.2012; 7: 95–99.
(check this in PDF content)
28
O'Donnell D.E., Laveneziana P., Ora J. et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009; 64: 216–223.
(check this in PDF content)
29
Johansson G., Lindberg A., Romberg K. et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim. Care Respir. J.2008; 17: 169–175.
(check this in PDF content)
30
Beeh K.M., Beier J., Buhl R. et al. Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities [Article in German]. Pneumologie. 2006; 60: 341–346. Поступила 29.11.16
(check this in PDF content)